Agenus Inc. (NASDAQ:AGEN) Short Interest Update

Agenus Inc. (NASDAQ:AGEN) was the target of a significant drop in short interest in October. As of October 31st, there was short interest totalling 2,800,000 shares, a drop of 10.5% from the October 15th total of 3,130,000 shares. Currently, 13.2% of the shares of the stock are sold short. Based on an average daily volume of 393,300 shares, the short-interest ratio is presently 7.1 days.

Hedge Funds Weigh In On Agenus

A number of institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its stake in shares of Agenus by 81.3% in the 1st quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 84,477 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Agenus by 13.7% in the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after purchasing an additional 4,134,232 shares during the period. Acadian Asset Management LLC increased its position in Agenus by 1,959.9% during the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 720,629 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Agenus by 52.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 123,058 shares during the period. Finally, Ovata Capital Management Ltd purchased a new stake in shares of Agenus in the 2nd quarter valued at approximately $670,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Price Performance

AGEN opened at $2.72 on Monday. The firm has a market capitalization of $63.81 million, a price-to-earnings ratio of -0.24 and a beta of 1.39. The company’s 50 day simple moving average is $4.70 and its two-hundred day simple moving average is $8.64. Agenus has a 1-year low of $2.58 and a 1-year high of $19.69.

Wall Street Analyst Weigh In

AGEN has been the subject of several research analyst reports. B. Riley reduced their price target on shares of Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. HC Wainwright reduced their target price on Agenus from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Tuesday, November 12th. Finally, StockNews.com downgraded Agenus from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $10.00.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.